Abbott Laboratories annual free cash flow
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Abbott Laboratories Free Cash Flow (FCF) History (ABT)
Abbott Laboratories reported $7.39B in free cash flow for fiscal 2025, an increase of 16.44% from the previous fiscal year, with a free cash flow margin of 16.68%.
View full Abbott Laboratories company overviewAbbott Laboratories free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.39B | $1.04B | +16.44% | +16.68% |
| 2024 | 2024-12-31 | $6.35B | $1.29B | +25.54% | +15.14% |
| 2023 | 2023-12-31 | $5.06B | −$2.75B | −35.17% | +12.61% |
| 2022 | 2022-12-31 | $7.80B | −$844.0M | −9.76% | +17.88% |
| 2021 | 2021-12-31 | $8.65B | $2.92B | +51.08% | +20.08% |
| 2020 | 2020-12-31 | $5.72B | $1.23B | +27.26% | +16.54% |
| 2019 | 2019-12-31 | $4.50B | −$408.0M | −8.32% | +14.10% |
| 2018 | 2018-12-31 | $4.91B | $471.0M | +10.62% | +16.04% |
| 2017 | 2017-12-31 | $4.43B | $2.35B | +113.02% | +16.19% |
| 2016 | 2016-12-31 | $2.08B | $226.0M | +12.18% | +9.98% |
| 2015 | 2015-12-31 | $1.86B | −$742.0M | −28.56% | +9.10% |
| 2014 | 2014-12-31 | $2.60B | $419.0M | +19.23% | +12.83% |
| 2013 | 2013-12-31 | $2.18B | −$5.34B | −71.02% | +11.09% |
| 2012 | 2012-12-31 | $7.52B | $40.0M | +0.53% | +39.47% |
| 2011 | 2011-12-31 | $7.48B | −$241.9M | −3.13% | +34.94% |
| 2010 | 2010-12-31 | $7.72B | $1.53B | +24.81% | +21.96% |
| 2009 | 2009-12-31 | $6.19B | $479.2M | +8.40% | +20.11% |
| 2008 | 2008-12-31 | $5.71B | $2.18B | +61.78% | +19.33% |
| 2007 | 2007-12-31 | $3.53B | — | — | +13.61% |
Abbott Laboratories quarterly free cash flow
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $916.0M | −$17.0M | −1.82% | +8.20% |
| Q4 2025 | 2025-12-31 | $2.63B | $478.0M | +22.25% | +22.92% |
| Q3 2025 | 2025-09-30 | $2.29B | $142.0M | +6.61% | +20.15% |
| Q2 2025 | 2025-06-30 | $1.54B | $118.0M | +8.27% | +13.87% |
| Q1 2025 | 2025-03-31 | $933.0M | $306.0M | +48.80% | +9.01% |
| Q4 2024 | 2024-12-31 | $2.15B | −$135.0M | −5.91% | +19.57% |
| Q3 2024 | 2024-09-30 | $2.15B | $832.0M | +63.17% | +20.21% |
| Q2 2024 | 2024-06-30 | $1.43B | $731.0M | +105.03% | +13.75% |
| Q1 2024 | 2024-03-31 | $627.0M | −$136.0M | −17.82% | +6.29% |
| Q4 2023 | 2023-12-31 | $2.28B | $567.0M | +33.04% | +22.29% |
| Q3 2023 | 2023-09-30 | $1.32B | −$996.0M | −43.06% | +12.98% |
| Q2 2023 | 2023-06-30 | $696.0M | −$1.33B | −65.73% | +6.98% |
| Q1 2023 | 2023-03-31 | $763.0M | −$981.0M | −56.25% | +7.83% |
| Q4 2022 | 2022-12-31 | $1.72B | −$737.0M | −30.04% | +17.01% |
| Q3 2022 | 2022-09-30 | $2.31B | $73.0M | +3.26% | +22.22% |
| Q2 2022 | 2022-06-30 | $2.03B | $316.0M | +18.43% | +18.04% |
| Q1 2022 | 2022-03-31 | $1.74B | −$496.0M | −22.14% | +14.66% |
| Q4 2021 | 2021-12-31 | $2.45B | −$666.0M | −21.35% | +21.39% |
| Q3 2021 | 2021-09-30 | $2.24B | $670.0M | +42.68% | +20.50% |
| Q2 2021 | 2021-06-30 | $1.72B | $1.03B | +152.21% | +16.78% |
| Q1 2021 | 2021-03-31 | $2.24B | $1.89B | +530.99% | +21.42% |
| Q4 2020 | 2020-12-31 | $3.12B | $1.14B | +57.37% | +29.15% |
| Q3 2020 | 2020-09-30 | $1.57B | $23.0M | +1.49% | +17.73% |
| Q2 2020 | 2020-06-30 | $680.0M | $88.0M | +14.86% | +9.28% |
| Q1 2020 | 2020-03-31 | $355.0M | −$22.0M | −5.84% | +4.59% |
| Q4 2019 | 2019-12-31 | $1.98B | $684.0M | +52.70% | +23.84% |
| Q3 2019 | 2019-09-30 | $1.55B | −$282.0M | −15.42% | +19.16% |
| Q2 2019 | 2019-06-30 | $592.0M | −$354.0M | −37.42% | +7.42% |
| Q1 2019 | 2019-03-31 | $377.0M | −$456.0M | −54.74% | +5.00% |
| Q4 2018 | 2018-12-31 | $1.30B | $3.0M | +0.23% | +16.72% |
| Q3 2018 | 2018-09-30 | $1.83B | $87.0M | +4.99% | +23.89% |
| Q2 2018 | 2018-06-30 | $946.0M | −$150.0M | −13.69% | +12.18% |
| Q1 2018 | 2018-03-31 | $833.0M | $531.0M | +175.83% | +11.27% |
| Q4 2017 | 2017-12-31 | $1.29B | $444.0M | +52.17% | +17.06% |
| Q3 2017 | 2017-09-30 | $1.74B | $837.0M | +92.49% | +25.51% |
| Q2 2017 | 2017-06-30 | $1.10B | $434.0M | +65.56% | +16.51% |
| Q1 2017 | 2017-03-31 | $302.0M | $638.0M | — | +4.77% |
| Q4 2016 | 2016-12-31 | $851.0M | $271.0M | +46.72% | +15.96% |
| Q3 2016 | 2016-09-30 | $905.0M | $121.0M | +15.43% | +17.07% |
| Q2 2016 | 2016-06-30 | $662.0M | −$63.0M | −8.69% | +12.41% |
| Q1 2016 | 2016-03-31 | −$336.0M | −$103.0M | — | −6.88% |
| Q4 2015 | 2015-12-31 | $580.0M | −$371.0M | −39.01% | +11.18% |
| Q3 2015 | 2015-09-30 | $784.0M | −$140.0M | −15.15% | +15.22% |
| Q2 2015 | 2015-06-30 | $725.0M | $83.0M | +12.93% | +14.02% |
| Q1 2015 | 2015-03-31 | −$233.0M | −$314.0M | — | −4.76% |
| Q4 2014 | 2014-12-31 | $951.0M | −$371.0M | −28.06% | +17.76% |
| Q3 2014 | 2014-09-30 | $924.0M | $679.0M | +277.14% | +18.19% |
| Q2 2014 | 2014-06-30 | $642.0M | $216.0M | +50.70% | +12.70% |
| Q1 2014 | 2014-03-31 | $81.0M | −$105.0M | −56.45% | +1.70% |
| Q4 2013 | 2013-12-31 | $1.32B | $205.1M | +18.36% | +26.06% |
| Q3 2013 | 2013-09-30 | $245.0M | −$2.74B | −91.80% | +5.10% |
| Q2 2013 | 2013-06-30 | $426.0M | −$1.22B | −74.05% | +8.64% |
| Q1 2013 | 2013-03-31 | $186.0M | −$1.59B | −89.50% | +3.84% |
| Q4 2012 | 2012-12-31 | $1.12B | −$10.1M | −0.90% | +19.83% |
| Q3 2012 | 2012-09-30 | $2.99B | $386.3M | +14.84% | +56.77% |
| Q2 2012 | 2012-06-30 | $1.64B | −$488.5M | −22.93% | +30.90% |
| Q1 2012 | 2012-03-31 | $1.77B | $152.3M | +9.40% | +33.53% |
| Q4 2011 | 2011-12-31 | $1.13B | −$898.1M | −44.35% | +10.86% |
| Q3 2011 | 2011-09-30 | $2.60B | $259.1M | +11.06% | +26.51% |
| Q2 2011 | 2011-06-30 | $2.13B | $55.4M | +2.67% | +22.15% |
| Q1 2011 | 2011-03-31 | $1.62B | $341.7M | +26.75% | +17.91% |
| Q4 2010 | 2010-12-31 | $2.03B | $438.0M | +27.60% | +20.32% |
| Q3 2010 | 2010-09-30 | $2.34B | −$358.0M | −13.25% | +27.01% |
| Q2 2010 | 2010-06-30 | $2.07B | $623.7M | +42.98% | +23.51% |
| Q1 2010 | 2010-03-31 | $1.28B | $831.0M | +186.10% | +16.60% |
| Q4 2009 | 2009-12-31 | $1.59B | — | — | +18.06% |
| Q3 2009 | 2009-09-30 | $2.70B | $322.7M | +13.57% | +34.80% |
| Q2 2009 | 2009-06-30 | $1.45B | — | — | +19.36% |
| Q1 2009 | 2009-03-31 | $446.6M | — | — | +6.65% |
| Q3 2008 | 2008-09-30 | $2.38B | — | — | +31.72% |
Abbott Laboratories free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from $5.72B to $7.39B, a compound annual growth rate of 5.26%. Abbott Laboratories's latest reported quarter, Q1 2026, generated $916.0M in free cash flow, a decrease of 1.82% year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Abbott Laboratories source filings ↗Community posts
Abbott launches blood-based colorectal cancer screening test in the US
Abbott ($ABT) has launched SimpleScreen CRC in the United States, adding an FDA-approved blood test to its colorectal cancer screening portfolio. Freenome develops and manufactures the test, while Abbott holds exclusive commercialization ri ...
Abbott agrees to $385 million settlement over infant-formula recall claims
Abbott ($ABT) said it will pay $385 million to resolve a previously disclosed Justice Department investigation and lawsuit, together with claims brought by certain whistleblowers and state attorneys general. The matters concern manufacturin ...
